Press release
Significant Number of Pipeline Drugs to Surge Hereditary Angioedema Market beyond US$ 3.4 Billion by 2025 | Top Players CSL Behring, Shire Plc., Pharming Healthcare, Inc., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Arrowhead Pharmaceutic
Hereditary Angioedema
Download FREE PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1292
Novel delivery platforms adopted by manufacturers to drive the global market growth
Positive clinical trial results integrated with assured safety profiles to cater the unmet need of the disease are the major factors to augment the global hereditary angioedema market in the foreseeable period. For instance, in 2016, RNAi-based candidate ARC-F12 by Arrowhead Pharmaceuticals is currently in preclinical development and is a potential treatment for factor XII (F12) mediated diseases. The RNAi based candidate is expected to present opportunities in the treatment of hereditary angioedema, thus the Arrowhead is currently conducting studies to advance the candidate into the clinical trials. Furthermore, the novel gene therapy product candidate by Adverum Biotechnologies named AADVM-053 is presently in the preclinical trials for the treatment of patients HAE. ADVM-053 is an Adeno Associated Virus (AAV) based gene transfer vector that aims to provide persistent levels of human C1-esterase inhibitor (C1-INH) to potentially correct the deficiency state that can lead to life threatening attacks.
Browse 58 Market Data Tables and 32 Figures spread through 175 Pages and in-depth TOC on “Hereditary Angioedema Market”- Global Forecast to 2025
To know the latest trends and insights prevalent in the hereditary angioedema market, click the link below: https://www.coherentmarketinsights.com/market-insight/hereditary-angioedema-market-1292
The key players are adopting strategic collaborations and acquisitions for the development and expansion of the HAE portfolio and to accelerate respective pipelines for faster delivery of the products. For instance, In January 2018, BioCryst Pharmaceuticals and Idera Pharmaceuticals merged to create a new rare-disease company. The companies currently have two phase 3 clinical compounds, including BioCryst’s BCX7353 and Idera’s IMO-8400. In 2017, Diplomat Pharmacy, Inc. acquired Focus Rx Pharmacy Services Inc., to offer extensive solutions to meet growing demand for infusion therapies for individuals living with chronic conditions including hereditary angioedema and other disorders. In 2015, Shire Plc acquired Dyax Corp. with a strategy to get access and achieve worldwide sales of lead pipeline product DX-2930, Phase 3-ready, fully humanized monoclonal antibody. The FDA granted DX-2930 fast track, breakthrough therapy, and orphan drug designation in the EU.
Key Takeaways of the Hereditary Angioedema Market:
- The global hereditary angioedema market is expected to exhibit a CAGR of 9.1% over the forecast period, owing to the presence of high potential market and rising awareness of the condition in Europe, Asia Pacific, and Latin America
- Among drug class, C1 esterase inhibitor segment holds a dominant position in the hereditary angioedema market, owing to the robust number of drugs approved by the regulatory agencies
- Some of the major players operating in the global hereditary angioedema market include CSL Behring, Shire Plc., Pharming Healthcare, Inc., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Adverum Biotechnologies and Attune Pharmaceuticals, Inc.
Buy This Exclusive Report @ https://www.coherentmarketinsights.com/insight/buy-now/1292
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Significant Number of Pipeline Drugs to Surge Hereditary Angioedema Market beyond US$ 3.4 Billion by 2025 | Top Players CSL Behring, Shire Plc., Pharming Healthcare, Inc., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Arrowhead Pharmaceutic here
News-ID: 1822302 • Views: …
More Releases from CMI - Pharmaceutical Industry
Empty Capsules Market to Surpass US$ 2.79 Billion Threshold by 2025 Globally | L …
The Global Empty Capsules Market by Product Type (Gelatin Capsules (Porcine, Bovine, and Bone Meal), Non-Gelatin Capsules (HPMC and Pullulan)), By Application (Antibiotics, Vitamins, Anti-Inflammatory, Anti-Anemic and Others), By End User (Pharmaceutical Manufacturers, Nutraceutical Manufacturers and Others), and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 1.55 billion in 2016 and is projected to exhibit a CAGR of 7.7% over the…
Ulcerative Colitis Market to Incur Fortitude Growth During 2018-2026 by Global T …
Ulcerative colitis is the most common type of inflammatory bowel disease that affects the colon (lining of the large intestine) and rectum. The inflammation produces tiny sores called ulcers. These disease can affect people of any age, though prevalence is especially high among people under 30 years of age. The major symptoms of this disease are diarrhea, belly pain/cramps, bleeding from the rectum, also other indications are sudden and unexplained…
PD-1 and PDL-1 Inhibitors Market - Global Industry Insights, Trends, Outlook, an …
Targeted cancer therapy is the primary objective of extensive research related to cancer drugs. Our immune cells are programmed to attack the foreign cell on activation. PD-1 and PDL-1 are among those activation points present on the immune cells. Sometimes cancer cells also use this PD-1 and PDL-1 trigger points to avoid being attacked by the immune cells. Therefore, cancer drugs targeting these cells hold tremendous potential in the cancer…
Dermal Regeneration Template Market - Global Industry Insights, Trends, Outlook, …
Dermal regeneration template is a two-layered skin regeneration system. The outer layer of dermal regeneration template is made of thin silicone film act as the epidermis of skin. The outer layer of dermal regeneration template helps in protecting wound from infection and controls in loss of both heat and moisture. The outer collagen Glycosaminoglycan (GAG) thermal layer functions as a biodegradable template that helps in regeneration of dermal tissue neodermis…
More Releases for Hereditary
Hereditary Angioedema Market: An In-Depth Analysis
In 2024, the market for Hereditary Angioedema Market was valued at USD 3.1 billion. It is anticipated to grow to USD 5.9 billion by 2033, with a CAGR of 6.82% over the period 2026-2033.
Hereditary Angioedema Market Overview
The global hereditary angioedema therapeutics market is experiencing significant expansion, driven by increasing awareness, improved diagnostic capabilities, and the introduction of novel treatment options. Advances in genetic research have enabled early and accurate…
Leber Hereditary Optic Neuropathy Treatment Market
Introduction
Leber Hereditary Optic Neuropathy (LHON) is a genetic condition that leads to severe vision loss, primarily affecting young adults. This disorder is caused by mutations in mitochondrial DNA, which impairs the function of retinal ganglion cells. As awareness of LHON has grown, so too has the focus on its treatment options. The LHON treatment market is evolving rapidly, driven by advancements in genetic therapies, pharmaceuticals, and supportive care strategies. This…
Hereditary Hemochromatosis Market - Redefining Care, Inspiring Hope: Hereditary …
Newark, New Castle, USA: The "Hereditary Hemochromatosis Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Hereditary Hemochromatosis Market: https://www.growthplusreports.com/report/hereditary-hemochromatosis-market/8793
This latest report researches the industry structure, sales, revenue,…
Hereditary Angioedema Market Research Report 2032
DelveInsight's "Hereditary Angioedema Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the Hereditary Angioedema, historical and forecasted epidemiology as well as the Hereditary Angioedema market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Hereditary Angioedema (HAE) is a rare genetic disorder caused by the deficiency in functional C1 inhibitor (C1INH) that results in recurrent attacks of localized subcutaneous or…
Hereditary Angioedema - Drug Pipeline Landscape, 2022
Global Hereditary Angioedema Market report from Global Insight Services is the single authoritative source of intelligence on hereditary angioedema market. The report will provide you with analysis of impact of latest market disruptions such as Russia-Ukraine war and Covid-19 on the market. Report provides qualitative analysis of the market using various frameworks such as Porters' and PESTLE analysis. Report includes in-depth segmentation and market size data by categories, product types,…
Hereditary Angioedema - Drug Pipeline Landscape, 2022
Hereditary Angioedema is an infrequent inherited disease that causes substantial swelling in various body tissues, such as the abdomen or face caused by a low level or improper function of a protein called the C1 inhibitor. There are three types of hereditary angioedema namely type I, II, and III.
Hereditary Angioedema is mainly caused by a low level or improper function of a protein called the C1 inhibitor.
Read more about Hereditary…
